Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach
- Frontiers Production Office, Frontiers, Lausanne, Switzerland
by Platania, C. B. M., Di Paola, L., Leggio, G. M, Romano, G. L., Drago, F., Salomone, S., et al. (2015) Front. Pharmacol. 6:248. doi: 10.3389/fphar.2015.00248
Reason for Erratum:
Due to a typesetting error, the article was published with incorrect values in Table 4. The publisher apologizes for this error and the correct version of Table 4 appears below. This error does not change the scientific conclusions of the article in any way.
Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., et al. (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171–185. doi: 10.1007/s10456-011-9249-6
Keywords: ranibizumab, bevacizumab, aflibercept, diabetic retinopathy, molecular dynamics
Citation: Frontiers Production Office (2016) Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Front. Pharmacol. 7:165. doi: 10.3389/fphar.2016.00165
Received: 01 June 2016; Accepted: 01 June 2016;
Published: 06 June 2016.
Approved by:Pharmacology Editorial Office, Frontiers, Switzerland
Copyright © 2016 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, email@example.com